CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

CARGO Therapeutics, Inc. Common Stock

CARGO Therapeutics is engineering best-in-class CAR T-cell therapy to overcome resistance to cancer treatment and address barriers to access so that more patients may benefit from potentially curative therapies. CARGO is on a mission to outsmart cancer by advancing a new generation of best-in-class chimeric antigen receptor (CAR) T-cell therapies. Despite advances made by commercially available autologous CARs, these treatments are curative for fewer than half of all cancer patients. In addition, far too many patients are unable to access these potentially curative therapies due to other challenges, including manufacturing, supply constraints, slow turnaround time and reimbursement hurdles. The team at CARGO is intensely focused on pursuing novel solutions to achieve better cancer treatment outcomes and experiences.

CARGO Therapeutics

Today we announced the appointment of Michael Ports, PhD, as Chief Scientific Officer. In this role at CARGO, Dr. Ports will be responsible for advancing our proprietary platform technologies and discovery-stage programs. Learn more: https://bit.ly/45QfufU

Today at the 8th CAR-TCR Summit in Boston, John Rossi, CARGO’s Vice President and Head of Translational Medicine, is presenting on strategies to deliver next generation engineered CAR T-cell therapy products to overcome resistance. John is also participating in a roundtable discussion on mechanisms of resistance and how to overcome them. Learn more here: https://lnkd.in/dn-KZVN 
#CARTCR #celltherapy #CART

Today we announced the addition of independent directors to our Board of Directors, bringing together an esteemed group of experienced life science leaders with expertise spanning finance, business operations, drug discovery and clinical development, including experts and pioneers in #CART therapies and #oncology. Learn more: https://bit.ly/47KuJIs

At CARGO, we are on a mission to advance next generation #CART therapies – and we are growing! We’re currently searching for a Medical Director to join our team. In this role, you’ll leverage your strong experience working across the clinical team to identify, influence and support priority initiatives while contributing to the leadership team and the advancement of CARGO cell therapy products. Review the job description here: https://lnkd.in/gRZYD2_3
#hiring #biotechjobs #celltherapy


Congratulations to our co-founder Crystal Mackall, MD, who was recently featured in an Endpoints News special report on 20 women reshaping biopharma for her pioneering work in the CAR T-cell therapy and oncology fields and her commitment to advocating for the next generation of women in biopharma! https://bit.ly/45qvyEz 
#CART #celltherapy #oncology

We are thrilled to participate in WuXi AppTec's BOLD: Innovation That Matters online series today! Our CEO Gina Simmons Chapman shares more about our work to advance #CART therapies for cancer during the spotlight session on the next wave of cancer therapeutics. Learn more and tune in here: https://bit.ly/43s85kM #TakingBOLDAction 

	Dec '21	Dec '22	Dec '23
average inventory
average payables		2.15M -	4.25M 97.54%
average receivables		238K -	1.11M 365.34%
book value per share
capex per share
capex to depreciation	-3.01 -	-2.27 24.41%	-2.44 7.16%
capex to operating cash flow	0.09 -	0.11 26.22%	0.11 1.86%
capex to revenue
cash per share
days of inventory on hand
days payables outstanding
days sales outstanding
debt to assets	0.70 -	2.34 233.17%	0.06 97.31%
debt to equity	-18.10 -	-0.68 96.24%	0.07 110.33%
enterprise value	3.13M -	22.13M 607.77%	-377.19M 1,804.28%
enterprise value over ebitda	-0.55 -	-0.66 21.04%
ev to operating cash flow	-0.63 -	-0.76 20.32%	4.65 710.45%
ev to sales
free cash flow per share
free cash flow yield
graham net net
graham number
income quality	0.84 -	0.71 15.96%	0.83 16.49%
intangibles to total assets	0 -	0	0
interest coverage		-7.04 -
interest debt per share
inventory turnover
invested capital	-18.10 -	-0.68 96.24%	0.07 110.33%
market cap
net current asset value	-4.50M -	-41.55M 824.40%	361.83M 970.78%
net debt to ebitda	-0.55 -	-0.66 21.04%
net income per share
operating cash flow per share
payables turnover
receivables turnover
research and ddevelopement to revenue
return on tangible assets	-1.30 -	-4.00 207.81%
revenue per share
roe	33.43 -	1.16 96.52%
roic	-0.99 -	4.26 530.20%
sales general and administrative to revenue
shareholders equity per share
stock based compensation to revenue
tangible asset value	-175K -	-35.24M 20,034.86%	405.39M 1,250.49%
tangible book value per share
working capital	-2.27M -	-40.21M 1,675.28%	388.31M 1,065.72%

CRGX

COM:CARGO-TX

CARGO Therapeutics

Last Close

15.73

22/11 21:00

Market Cap

761.31M

Beta: -

Volume Today

156.59K

Avg: -

Preview